Canaccord Genuity Reaffirms Buy Rating for Smith & Nephew (NYSE:SNN)

Canaccord Genuity reissued their buy rating on shares of Smith & Nephew (NYSE:SNN) in a research report report published on Friday, January 5th. The firm currently has a $45.00 target price on the medical equipment provider’s stock.

SNN has been the subject of several other reports. Zacks Investment Research upgraded Smith & Nephew from a hold rating to a buy rating and set a $43.00 price target for the company in a research note on Wednesday, October 18th. Morgan Stanley downgraded Smith & Nephew from an overweight rating to an equal weight rating in a research report on Monday, December 11th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $44.00.

Smith & Nephew (NYSE SNN) opened at $36.53 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.18 and a quick ratio of 1.08. Smith & Nephew has a 12 month low of $29.76 and a 12 month high of $40.43.

Institutional investors and hedge funds have recently modified their holdings of the stock. Bessemer Group Inc. boosted its holdings in Smith & Nephew by 400.2% in the third quarter. Bessemer Group Inc. now owns 2,781 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 2,225 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Smith & Nephew in the fourth quarter valued at about $126,000. Lbmc Investment Advisors LLC purchased a new position in Smith & Nephew in the third quarter valued at about $206,000. First Allied Advisory Services Inc. purchased a new position in Smith & Nephew in the third quarter valued at about $247,000. Finally, Quantbot Technologies LP boosted its holdings in Smith & Nephew by 270.0% in the second quarter. Quantbot Technologies LP now owns 7,277 shares of the medical equipment provider’s stock valued at $253,000 after purchasing an additional 5,310 shares during the last quarter. 6.44% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Canaccord Genuity Reaffirms Buy Rating for Smith & Nephew (NYSE:SNN)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/01/smith-nephew-snn-earns-buy-rating-from-canaccord-genuity.html.

Smith & Nephew Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply